Noida Chronicle

DelveInsight’s, “Transforming growth factor beta inhibitors Pipeline Insights 2023” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on Transforming growth factor beta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Transforming Growth factor beta inhibitors Emerging drugs, the Transforming Growth factor beta inhibitors pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Transforming Growth factor beta inhibitors pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Transforming Growth factor beta inhibitors Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Transforming Growth factor beta inhibitors clinical trials studies, Transforming Growth factor beta inhibitors NDA approvals (if any), and product development activities comprising the technology, Transforming Growth factor beta inhibitors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Transforming Growth factor beta inhibitors Pipeline report

 

• DelveInsight’s Transforming Growth factor beta inhibitors Pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Transforming Growth factor beta inhibitors treatment.

 

• The leading Transforming Growth factor beta inhibitors Companies include Oncotelic, Jiangsu Hengrui Medicine Co, Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.

 

• Promising Transforming Growth factor beta inhibitors Pipeline Therapies include Trabedersen, KER-050, STP705, and others.

 

• The Transforming Growth factor beta inhibitors Companies and academics that are working to assess challenges and seek opportunities that could influence Transforming Growth factor beta inhibitors R&D. The Transforming Growth factor beta inhibitors pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the Transforming Growth factor beta inhibitors Pipeline treatment landscape of the report, click here @ Transforming Growth factor beta inhibitors Pipeline Outlook

 

Transforming Growth factor beta inhibitors Overview

Transforming growth factor-β (TGF-β) regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immunity. It has a paradoxical role in cancer. In the early stages it inhibits cellular transformation and prevents cancer progression. In later stages TGF-β plays a key role in promoting tumor progression through mainly 3 mechanisms: facilitating epithelial to mesenchymal transition, stimulating angiogenesis and inducing immunosuppression.

 

Recent Developmental Activities in the Treatment Landscape

 

• ALK5 inhibitor galunisertib (LY2157299) blocks the TGF- signalling pathway by selectively inhibiting the activation of the downstream molecule Smad with an IC50 of 50 nM. Patients with uterine or ovarian carcinosarcoma are presently being tested for response to galunisertib in a phase I clinical trial in combination with Paclitaxel or Carboplatin. (NCT03206177). Galunisertib and Enzalutamide, a non-steroidal anti-androgen, are being tested in a phase II clinical study on patients with metastatic castration-resistant prostate cancer. (NCT02452008).

 

• Vactosertib (TEW-7197), a new orally bioavailable inhibitor of ALK5 with an IC50 of 11 nM, was created to be more potent and specific than other small molecule inhibitors. Phase I/II clinical trials using vactosertib in combination with conventional chemotherapeutic agents are presently being conducted for a number of cancer types. Both the safety and effectiveness of Vactosertib in combination with Paclitaxel in patients with metastatic gastric cancer (NCT03698825) and in combination with Pomalidomide, a thalidomide analogue in patients with relapsed and refractory multiple myeloma are presently being examined in two phase I clinical trials. (NCT03143985). In clinical trials, Vactosertib combined with Imatinib is being researched for individuals with advanced desmoid tumour. (NCT03802084).

 

• In clinical studies, SRK-181 is being used both alone and in conjunction with an anti-PD-L1 antibody to treat patients with locally advanced or metastatic solid tumours. (NCT04291079).

  

For further information, refer to the detailed Transforming Growth factor beta inhibitors Unmet Needs, Transforming Growth factor beta inhibitors Market Drivers, and Transforming Growth factor beta inhibitors Market Barriers, click here for Transforming Growth factor beta inhibitors Ongoing Clinical Trial Analysis

 

Transforming growth factor beta inhibitors Emerging Drugs

 

• Trabedersen: Oncotelic

Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-β2 messenger RNA. Ready for registration trials–Over 200 patients treated across 6 clinical trials. It has Potential for breakthrough designation for early approval. It is in phase III stage of development.

 

• KER-050: Keros Therapeutics

KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.

 

• STP705: Sirnaomics

STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size. It is currently in phase II stage of development.

 

Transforming Growth factor beta inhibitors Pipeline Therapeutics Assessment

There are approx. 90+ key companies which are developing the therapies based on Transforming growth factor beta inhibitors. The companies which have their drug candidate based on Transforming growth factor beta inhibitors in the most advanced stage, i.e. phase III include Oncotelic and others

 

Request a sample and discover the recent advances in Transforming Growth factor beta inhibitors Ongoing Clinical Trial Analysis and Medications, click here @ Transforming Growth factor beta inhibitors Treatment Landscape

 

Scope of the Transforming Growth factor beta inhibitors Pipeline Report

 

• Coverage- Global

 

• Transforming Growth factor beta inhibitors Companies- Oncotelic, Jiangsu Hengrui Medicine Co, Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.

 

• Transforming Growth factor beta inhibitors Pipeline Therapies- Trabedersen, KER-050, STP705, and others.

 

• Transforming Growth factor beta inhibitors Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Transforming Growth factor beta inhibitors Market Drivers and Transforming Growth factor beta inhibitors Market Barriers, click here @ Transforming Growth factor beta inhibitors Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Transforming growth factor beta inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Transforming growth factor beta inhibitors – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Transforming growth factor beta inhibitors Collaboration Deals
9. Late Stage Products (Phase III)
10. Trabedersen: Oncotelic
11. Mid Stage Products (Phase II)
12. KER-050: Keros Therapeutics
13. STP705: Sirnaomics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Pre-clinical and Discovery Stage Products
19. Drug Name: Company Name
20. Inactive Products
21. Transforming growth factor beta inhibitors Key Companies
22. Transforming growth factor beta inhibitors Key Products
23. Transforming growth factor beta inhibitors- Unmet Needs
24. Transforming growth factor beta inhibitors- Market Drivers and Barriers
25. Transforming growth factor beta inhibitors- Future Perspectives and Conclusion
26. Transforming growth factor beta inhibitors Analyst Views
27. Transforming growth factor beta inhibitors Key Companies
28. Appendix

 

Got Queries? Find out the related information on Transforming Growth factor beta inhibitors Mergers and acquisitions, Transforming Growth factor beta inhibitors Licensing Activities @ Transforming Growth factor beta inhibitors Emerging Drugs, and Recent Trends

 

About Us 

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/